16 September 2026
16 September 2026
Hyperfine plans to use the data to support its first expanded indication submission for the Swoop system since FDA clearance.
QurCan will optimise genetic therapeutics using its technology, with Lilly overseeing further research and commercialisation.
The arrangement covers BRAINBox’s tests for TBI, also called mild TBI or acute traumatic encephalopathy.
The study assessed zipalertinib plus chemotherapy versus chemotherapy alone as first-line treatment.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
